Bryan Garnier - AELIS FARMA SA (AELIS) Aelis: Reaffirming confidence ahead of major clinical readouts

Report

Bryan Garnier

Oscar Haffen Lamm ...

Valliant Campagne

Aelis: Reaffirming confidence ahead of major clinical readouts

2024 is set to be a pivotal year for Aelis with readouts on both of its assets (AEF0117 and AEF0217) scheduled for after the '24 summer break. Aelis' lead asset AEF0117, a signaling-specific inhibitor of the CB1-SSi, is currently being investigated in a phase 2b trial in patients suffering from can

17/04/2024 1 EN

Underlying

AELIS FARMA SA

See profile

FR0014007ZB4 Euronext Paris France

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Oscar Haffen Lamm

Valliant Campagne

Other Reports on these Companies

BusinessWire

Aelis Farma : Mise à disposition du Document d’Enregistrement Universel 2023

BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: Aelis Farma (ISIN : FR0014007ZB4 – Mnémonique : AELIS, éligible PEA-PME), société biopharmaceutique au stade clinique spécialisée dans le développement de traitements pour les maladies du cerveau, annonce la mise à disposition de son Document d’Enregistrement Universel 2023 approuvé par l’Autorité des marchés financiers (AMF), le 24 avril 2024 sous le numéro R.24-004. Le Document d'Enregistrement Universel 2023 inclut notamment : le rapport financier annuel 2023 ; les rapports du Commissaire aux Comptes ; les informations relati...

April 25, 2024 April 25, 2024 1 FR

BusinessWire

Aelis Farma annonce la dernière visite du dernier patient (Last Patient Last Visit ou LPLV) de l’étude de phase 2b avec AEF0117 dans le traitement de l’addiction au cannabis

BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: Aelis Farma (ISIN : FR0014007ZB4 – Mnémonique : AELIS, éligible PEA-PME), société biopharmaceutique au stade clinique spécialisée dans le développement de traitements pour les maladies du cerveau, annonce le franchissement d’une nouvelle étape dans le développement clinique de AEF0117 avec la réalisation de la dernière visite médicale du dernier patient inclus dans l’étude de phase 2b ayant inclus 333 patients souffrant d’addiction au cannabis ou CUD (Cannabis Use Disorder). AEF0117 est le premier représentant d’une nouvelle classe de mé...

April 18, 2024 April 18, 2024 1 FR

Nemetschek - SaaS momentum accelerates in Q1 2024

Nemetschek delivered solid growth in Q1 2024, with a homogenous contribution from every division. The quarter was marked by the acceleration of SaaS and subscription revenue (+68% Y/Y) and a confirmation of both short term and long-term growth objectives (+10-11% in FY2024e and >+15% in FY2025e)

6h / 5m 6h / 5m 1 EN

Paul de Froment ... (+3)

Paul de Froment
Sebastián Marroquin Mérida
Thomas Mordelle

Waga Energy: Setting itself for profitable growth

Waga Energy has reported a FY 2023 EBIT loss broadly in line with expectations at EUR14.1m (vs cons. at -EUR14.2m). With 23 units in operation (0.9TWh/year), 14 under construction representing up to 1.3TWh/year of additional capacity, and a global pipeline of more than 12TWh/year, Waga Energy is on

6h / 35m 6h / 35m 1 EN

Aurelien Deside

Aurelien Deside

Exclusive Networks: Q1 growth dampened by high comps as expected

Yesterday evening, EXN reported Q1 2024 results in line with our estimates, suffering the effects of exceptionally high Q1 2023 comps. The group also reiterated its FY guidance and provided more details on its NEXTGEN acquisition.

7h / 5m 7h / 5m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Aelis: Reaffirming confidence ahead of major clinical readouts

Aelis Farma : Mise à disposition du Document d’Enregistrement Universel 2023

Aelis Farma annonce la dernière visite du dernier patient (Last Patient Last Visit ou LPLV) de l’étude de phase 2b avec AEF0117 dans le traitement de l’addiction au cannabis

Nemetschek - SaaS momentum accelerates in Q1 2024

Waga Energy: Setting itself for profitable growth

Exclusive Networks: Q1 growth dampened by high comps as expected

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe